Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Mayumi Nakagawa

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPathology, College of Medicine
DivisionPathology Clinical
AddressM1/321 Central Building (old hospital)
4301 W.Markham
Mail Slot # 502
Little Rock AR 72205
Phone501-686-8635
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant. SAGE Open Med. 2018; 6:2050312118800202. PMID: 30245818.
      View in: PubMed
    2. Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260. PMID: 29414659.
      View in: PubMed
    3. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73. PMID: 26980480; PMCID: PMC4841729 [Available on 05/01/17].
    4. Moerman-Herzog A, Nakagawa M. Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol. 2015 Aug; 22(8):850-7. PMID: 26063238; PMCID: PMC4519724.
    5. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015 Oct; 4(10):e1031439. PMID: 26451301.
      View in: PubMed
    6. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87. PMID: 25947147; PMCID: PMC4478515.
    7. Stratton SL, Spencer HJ, Greenfield WW, Low G, Hitt WC, Quick CM, Jeffus SK, Blackmon V, Nakagawa M. A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. Clin Trials. 2015 Jun; 12(3):199-204. PMID: 25576067; PMCID: PMC4424105.
    8. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (KoateĀ®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
      View in: PubMed
    9. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. Bone Marrow Res. 2014; 2014:891427. PMID: 24876970; PMCID: PMC4024409.
    10. Coleman HN, Wang X, Greenfield WW, Nakagawa M. A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot. MOJ Immunol. 2014; 1(3). PMID: 25685851.
      View in: PubMed
    11. Nakagawa M, Coleman HN, Wang X, Daniels J, Sikes J, Nagarajan UM. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine. 2014 Feb; 65(2):202-9. PMID: 24301038; PMCID: PMC3907066.
    12. Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013 Dec 02; 31(49):5806-13. PMID: 24135577; PMCID: PMC3856859.
    13. Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc. 2013 Jan; 109(8):160-3. PMID: 23367687; PMCID: PMC3594117.
    14. Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apher Sci. 2013 Feb; 48(1):35-8. PMID: 22842111.
      View in: PubMed
    15. Wang X, Greenfield WW, Coleman HN, James LE, Nakagawa M. Use of interferon-? enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus. J Vis Exp. 2012 Mar 08; (61). PMID: 22434036; PMCID: PMC3460593.
    16. Coleman HN, Moscicki AB, Farhat SN, Gupta SK, Wang X, Nakagawa M. CD8 T-cell responses in incident and prevalent human papillomavirus types 16 and 18 infections. ISRN Obstet Gynecol. 2012; 2012:854237. PMID: 22523697; PMCID: PMC3316950.
    17. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70. PMID: 21842207; PMCID: PMC3374341.
    18. Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec; 146(12):1431-3. PMID: 21173332.
      View in: PubMed
    19. Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottler-Fox M, Pesek G, Theus J, Nakagawa M. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion. 2011 May; 51(5):1030-6. PMID: 20946201.
      View in: PubMed
    20. Kim KH, Horn, T, Pharis, J, Kincannon, J, Jones, R, O'Bryan, K, Myers, J, Nakagawa M. Phase I clinical trial of intralesional injection of Candida antigen for treating warts. 2010.
    21. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9. PMID: 20354421.
      View in: PubMed
    22. Kim, KH, Horn, T, Pharis, J, Kincannon, J, Jones, R, O'Bryan, K, Myers, J, Nakagawa M. Phase I clinical trial of intralesional injection of Candida antigen for treating warts. 2010.
    23. Nakagawa M, Gupta S, Coleman, H, Sellers, M, Banken, J, Greenfield, W. A favorable clinical trend is associated with CD8 T-Cell Responses to the Human papillomavirus Type 16 E6 Antigens in women being studied for abnormal Pap smear results. Journal of Lower Genital Tract Disease. 2010; 14:124-129.
    24. Farhat S, Nakagawa M, Moscicki A. Cell-meidated immune responses to humanpapillomavirus 16 E6 nad E7 antigens as measured by IFN gamma ELISpot in women woth cleared or persistent HPV infection. 2009; 19(4):508-12.
    25. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer. 2009 May; 19(4):508-12. PMID: 19509544.
      View in: PubMed
    26. Farhat, S, Nakagawa M. Cell-mediated immune reponses to humanpapillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. Int Journal of Gynecological Cancer. 2009; (19):508-512.
    27. Farhat, S, Nakagawa M, Moscicki, A. -B Cell-mediated immune reponses to human papillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. International Journal of Gynecological Cancer. 2009; (19):508-512.
    28. Nakagawa, M, Gupta, S, Coleman, H, Sellers, M, Banken, J, Greenfield, W. Regression is Associated with CD8 T-Cell Responses to the Human Papillomavirus Type 16 E6. 2009.
    29. Iijima K, Koike H, Ota H, Nakagawa M, Nishikawa K, Kotani K. [Structural homology between streptolysin O (SLO) produced by streptococcus pyogenes and SLO-like protein produced by non-pathogenic streptococci and cross-reactivity of antibody against SLO-like protein to SLO]. Rinsho Byori. 2008 Aug; 56(8):678-83. PMID: 18800623.
      View in: PubMed
    30. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol. 2008 Jun; 15(6):937-45. PMID: 18448624; PMCID: PMC2446617.
    31. Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother. 2009 Feb; 58(2):301-8. PMID: 18446336; PMCID: PMC2782377.
    32. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T-Cells Specific for Novel HPV 16 E6 Epitopes in Women Whose HPV 16 Infection Has Become Undetectable. Clin Vaccine Immunol. 2008.
    33. Kim KH, Greenfield W, Shotts E, Nakagawa M. Detection of human papillomavirus type 16-specific T lymphocytes by a recombinant vaccinia virus-based enzyme-linked immunospot assay. Clin Vaccine Immunol. 2007 Apr; 14(4):362-8. PMID: 17314231; PMCID: PMC1865606.
    34. Farhat S, Nakagawa M, Kim KH, Moscicki AB. A comparison between gamma interferon ELISPOT and chromium release assays to detect cell-mediated immune responses to human papillomavirus type 16 E6 and E7 antigens. 2007; In Preparation.
    35. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol. 2007 Feb; 81(3):1412-23. PMID: 17108051; PMCID: PMC1797519.
    36. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 2006 Jun 30; 6:9. PMID: 16808432.
      View in: PubMed
    37. Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5. PMID: 16085919; PMCID: PMC1182184.
    38. Tugizov S, Berline J, Herrera R, Penaranda ME, Nakagawa M, Palefsky J. Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J Virol. 2005 Jan; 79(2):1099-112. PMID: 15613338; PMCID: PMC538578.
    39. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion. 2004 Dec; 44(12):1683-8. PMID: 15584980.
      View in: PubMed
    40. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion. 2004 Dec; 44(12):1689-94. PMID: 15584981.
      View in: PubMed
    41. Nakagawa M, Dempsey DA, Haller C, Toy P. Safe lead levels: blood transfusion of extremely low birth weight infants. Clin Pediatr (Phila). 2004 Sep; 43(7):681. PMID: 15378161.
      View in: PubMed
    42. Nakagawa M, Kim KH, Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol. 2004 Sep; 11(5):889-96. PMID: 15358648; PMCID: PMC515262.
    43. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82. PMID: 12093689; PMCID: PMC120038.
    44. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001; 8(2):209 - 220.
    45. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis. 2000; 182(2):595 - 598.
    46. De JA, Palefsky JM, Stites DP, Nakagawa M. Human immunodeficiency virus-positive individuals with oral hairy leukoplakia are able to mount cytotoxic T lymphocyte responses to Epstein-Barr virus. Oral Dis. 2000; 6(1):40 - 47.
    47. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol. 1999; 6(4):494 - 498.
    48. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997; 175(4):927 - 931.
    49. Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol. 1997; 4(2):185 - 188.
    50. Nakagawa M, Stites DP, Farhat S, Judd A, Moscicki AB, Canchola AJ, Hilton JF, Palefsky JM. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol. 1996; 3(2):205 - 210.
    51. Zeff RA, Nakagawa M, Mashimo H, Gopas J, Nathenson SG. Failure of cell surface expression of a class I major histocompatibility antigen caused by somatic point mutation. Transplantation. 1990; 49(4):803 - 808.
    52. Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG. Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor. Cell. 1988; 54(1):47 - 56.
    53. Geliebter J, Ajit Kumar P, Boriello F, Hemmi S, Kesari K, Mashimo H, McGovern D, Nakagawa M, Palmieri-Lehner E, Pontarotti P, Pfaffenbach GM, Raval R, Trohnacki J, Zeff RA, Nathenson SG. Polymorphism and diversity in the murine class I gene family: A study of spontaneous mutants. Evolution and Vertebrate Immunity: The antigen-receptor and MHC gene families. 1987; 315-328.
    54. Zeff RA, Ajit Kumar P, Mashimo H, Nakagawa M, McCue B, Borriello F, Kesari K, Geliebter M, Hemmi S, Pfaffenbach G, Trohnacki J, McGovern D, Nathenson SG. Somatic cell variants of the murine major histocompatibility complex. Immunological Res. 1987; 6:133-144.
    55. Geliebter J, Ajit Kumar P, Borriello F, Hemmi S, Kesari K, Mashimo H, McCue B, Nakagawa M, Pfaffenbach GM, Zeff RA, Nathenson SG. Diversification of H-2 genes through recombination: A study of Kb mutants. Progress in Immunology VI. 1987; 186-196.
    56. Geliebter J, Ajit Kumar P, Borriello G, Hemmi S, Kaseri K, Mashimo H, Nakagawa M, Pontarotti P, Pfaffenbach GM, Zeff RA, Nathenson SG. The use of Class I mutants to study polymorphosm and diversity in the MHC. Perspectives in Immunogenetics and Histocompatibility. 1987; 7:43-50.
    57. Nakagawa M, Zeff RA, Geier SS, Bluestone JA, Nathenson SG. Somatic cell variants of H-2Kb: a point mutation in the first extracellular domain results in altered immune recognition. Immunogenetics. 1986; 24(6):381 - 385.
    58. Nathenson SG, Geliebter J, Geier SS, Mashimo H, Hemmi S, Kumar A, McGovern D, Nakagawa M, Pfaffenbach G, Pontatotti P, Zeff R. The study of H-2 major histocompatibility complex mutants reveals structure-function relationships and mechanisms of generation of diversity and polymorphism. ICSU Short Report, Advances in Gene Technology: Molecular Biology of the Immune System. 1985; 37-40.
    Nakagawa's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _